Back to Type 2 Diabetes
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT01904383

NCT01904383
Completed Not Applicable

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with type 2 diabetes and are currently taking medication to manage your blood sugar
  • You have never previously taken the medication called Trazenta® (linagliptin) before joining the trial

Who may not be able to join:

  • There are no listed exclusion criteria for this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
Boehringer Ingelheim
Registry
clinicaltrials_gov
Start date
1 July 2013
Est. completion
4 October 2018

Where this trial is recruiting

🇯🇵 Japan

Primary endpoints

Percentage of Participants With Drug Related Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov